AstraZeneca plc (LON:AZN) had its Overweight rating reiterated by Barclays

ME Staff
-
0

Analyst Ratings For

AstraZeneca plc (LON:AZN)

Today, Barclays reiterated its Overweight rating on

AstraZeneca plc (LON:AZN).

There are 10 Buy Ratings, 4 Hold Ratings, 3 Sell Ratings, no Strong Buy Ratings on the stock.

The current consensus rating on

AstraZeneca plc (LON:AZN) is Hold with a consensus target price of GBX 7,465.67 per share, a potential .

Some recent analyst ratings include

  • 11/18/2019-
    AstraZeneca plc (LON:AZN) had its Overweight rating reiterated by Barclays
  • 11/14/2019-
    AstraZeneca plc (LON:AZN) had its Buy rating reiterated by Shore Capital
  • 11/13/2019-
    AstraZeneca plc (LON:AZN) had its Buy rating reiterated by Deutsche Bank with a GBX 8,300 price target
  • 11/11/2019-
    AstraZeneca plc (LON:AZN) had its Sell rating reiterated by UBS Group with a GBX 5,800 price target
  • 11/11/2019-
    AstraZeneca plc (LON:AZN) had its Hold rating reiterated by Jefferies Financial Group with a GBX 6,700 price target
  • 11/11/2019-
    AstraZeneca plc (LON:AZN) had its Buy rating reiterated by Liberum Capital

    Recent Trading Activity for

    AstraZeneca plc (LON:AZN)
    Shares of

    AstraZeneca plc closed the previous trading session at 7,326.00 up +78.00 1.08% with 46.83 shares trading hands.